Thursday, July 30

Browsing: Armamentarium

Survivors

Cevostamab May Fill Gap in Multiple Myeloma Armamentarium

By NewsCancerMay 5, 20260

In a conversation with CancerNetwork®, Prerna Mewawalla, MD, discussed the potential clinical utility of targeting FcRH5 in the treatment of…

Survivors

NCCN Guidelines Add Novel Therapeutics to First-Line TNBC Armamentarium

By NewsCancerMarch 18, 20260

The National Comprehensive Cancer Network (NCCN) updated the Clinical Practice Guidelines in Oncology to recommend sacituzumab govitecan-hziy (Trodelvy) as a…

Treatments

Rusfertide May Become Part of Polycythemia Vera Armamentarium

By NewsCancerMarch 14, 20260

In March 2026, the FDA granted priority review to rusfertide as a potential treatment option for patients with polycythemia vera.…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

CAR T-Cell Therapy Could Soon Expand Into Non-Oncology Indications

TKTL1 mediates metabolic adaptation and stress resistance in pancreatic cancer cells under nutrient-deprived conditions

Browsing: Armamentarium

Cevostamab May Fill Gap in Multiple Myeloma Armamentarium

NCCN Guidelines Add Novel Therapeutics to First-Line TNBC Armamentarium

Rusfertide May Become Part of Polycythemia Vera Armamentarium

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

CAR T-Cell Therapy Could Soon Expand Into Non-Oncology Indications

TKTL1 mediates metabolic adaptation and stress resistance in pancreatic cancer cells under nutrient-deprived conditions

Capricor’s data clash with the FDA| STAT

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

CAR T-Cell Therapy Could Soon Expand Into Non-Oncology Indications

TKTL1 mediates metabolic adaptation and stress resistance in pancreatic cancer cells under nutrient-deprived conditions

Capricor’s data clash with the FDA| STAT

Latest Post

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

CAR T-Cell Therapy Could Soon Expand Into Non-Oncology Indications

TKTL1 mediates metabolic adaptation and stress resistance in pancreatic cancer cells under nutrient-deprived conditions

Subscribe to Updates

What's Hot

Browsing: Armamentarium